Sudarmadji 2009.

Methods	A double‐blind, randomised parallel trial of methylphenidate use for 2 weeks
Participants	Number of participants screened: not stated Number of participants included: 84 1 group randomised to 5 mg methylphenidate daily, other group to 10 mg methylphenidate daily (number of participants in each group not stated) Number followed up in each arm: not stated Number of withdrawals in each arm: not stated Diagnosis of ADHD: DSM‐IV (subtype: not stated) Age: mean not stated (range: 6‐14) IQ: above 70 (attending elementary school) Sex: not stated Methylphenidate‐naïve: not stated Ethnicity: not stated Country: Indonesia Comorbidity: not stated Comedication: not stated Sociodemographics: not stated Inclusion criteria: Attending 1 of 7 specific elementary schools 6‐14 years old Both sexes DSM‐IV diagnosis of ADHD Exclusion criteria: None stated
Interventions	Methylphenidate type: not stated Methylphenidate dosage: 5 mg or 10 mg Administration schedule: once daily Duration of intervention: 2 weeks Treatment compliance: not stated
Outcomes	No description of measures
Notes	Sample calculation: not stated Ethics approval: not stated Funding/vested interests: not stated Authors' affiliations: not stated Key conclusions of the study authors: treatment with 5 mg methylphenidate was more effective compared with 10 mg methylphenidate to improve the attention, decrease hyperactivity and increase the cognitive function. The side effects of 5 mg/daily methylphenidate were milder compared with 10 mg/daily Exclusion of methylphenidate non‐responders/children who have previously experienced adverse events on methylphenidate: not stated Supplemental information was attempted to be retrieved through contact with the authors in July 2014. We were not able to find contact information on any of the authors